Veru Inc. (NASDAQ:VERU - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.59 and traded as high as $0.60. Veru shares last traded at $0.58, with a volume of 814,360 shares changing hands.
Veru Stock Down 6.5%
The stock has a fifty day simple moving average of $0.59 and a 200 day simple moving average of $0.59. The firm has a market capitalization of $82.20 million, a P/E ratio of -2.34 and a beta of -0.75.
Veru (NASDAQ:VERU - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Research analysts anticipate that Veru Inc. will post -0.22 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Weaver Consulting Group grew its position in Veru by 27.4% in the first quarter. Weaver Consulting Group now owns 88,838 shares of the company's stock worth $44,000 after acquiring an additional 19,133 shares in the last quarter. Cetera Investment Advisers lifted its stake in Veru by 26.1% in the fourth quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after purchasing an additional 19,724 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Veru by 37.1% in the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company's stock worth $49,000 after purchasing an additional 20,430 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in Veru by 31.3% in the fourth quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock worth $56,000 after purchasing an additional 20,500 shares during the last quarter. Finally, Barclays PLC lifted its stake in Veru by 11.8% in the fourth quarter. Barclays PLC now owns 206,515 shares of the company's stock worth $134,000 after purchasing an additional 21,738 shares during the last quarter. Hedge funds and other institutional investors own 47.16% of the company's stock.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Read More
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
